EE03285B1 - Immuunsust stimuleerivad monoklonaalsed antikehad - Google Patents

Immuunsust stimuleerivad monoklonaalsed antikehad

Info

Publication number
EE03285B1
EE03285B1 EE9600107A EE9600107A EE03285B1 EE 03285 B1 EE03285 B1 EE 03285B1 EE 9600107 A EE9600107 A EE 9600107A EE 9600107 A EE9600107 A EE 9600107A EE 03285 B1 EE03285 B1 EE 03285B1
Authority
EE
Estonia
Prior art keywords
stimulated
immunity
monoclonal antibodies
tumor
elicts
Prior art date
Application number
EE9600107A
Other languages
English (en)
Estonian (et)
Inventor
Hardy Britta
Novogrodsky Avraham
Original Assignee
Mor Research Applications Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd. filed Critical Mor Research Applications Ltd.
Publication of EE03285B1 publication Critical patent/EE03285B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
EE9600107A 1994-01-31 1995-01-30 Immuunsust stimuleerivad monoklonaalsed antikehad EE03285B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies

Publications (1)

Publication Number Publication Date
EE03285B1 true EE03285B1 (et) 2000-08-15

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600107A EE03285B1 (et) 1994-01-31 1995-01-30 Immuunsust stimuleerivad monoklonaalsed antikehad

Country Status (20)

Country Link
US (1) US5897862A (ro)
EP (1) EP0742795B1 (ro)
JP (1) JP3478398B2 (ro)
CN (1) CN1052733C (ro)
AT (1) ATE171461T1 (ro)
AU (1) AU693526B2 (ro)
CA (1) CA2182289C (ro)
DE (1) DE69504955T2 (ro)
DK (1) DK0742795T3 (ro)
EE (1) EE03285B1 (ro)
ES (1) ES2124533T3 (ro)
FI (1) FI963004A (ro)
IL (1) IL108501A (ro)
LT (1) LT4225B (ro)
LV (1) LV11624B (ro)
MD (1) MD1374G2 (ro)
MX (1) MX9603080A (ro)
NO (1) NO317020B1 (ro)
RU (1) RU2155190C2 (ro)
WO (1) WO1995020605A1 (ro)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
WO2013014668A1 (en) 2011-07-24 2013-01-31 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
WO1995020605A1 (en) 1995-08-03
CA2182289A1 (en) 1995-08-03
LT96115A (en) 1997-05-26
US5897862A (en) 1999-04-27
CA2182289C (en) 2003-10-21
NO963168L (no) 1996-09-27
MD1374G2 (ro) 2000-09-30
NO963168D0 (no) 1996-07-29
IL108501A (en) 1998-10-30
DE69504955D1 (de) 1998-10-29
NO317020B1 (no) 2004-07-26
ES2124533T3 (es) 1999-02-01
JP3478398B2 (ja) 2003-12-15
LV11624A (en) 1996-12-20
ATE171461T1 (de) 1998-10-15
MX9603080A (es) 1998-01-31
DE69504955T2 (de) 1999-05-27
LV11624B (en) 1997-06-20
EP0742795A1 (en) 1996-11-20
CN1145077A (zh) 1997-03-12
FI963004A0 (fi) 1996-07-29
MD1374F2 (ro) 1999-12-31
LT4225B (en) 1997-10-27
CN1052733C (zh) 2000-05-24
JPH09508390A (ja) 1997-08-26
IL108501A0 (en) 1994-05-30
DK0742795T3 (da) 1999-06-14
FI963004A (fi) 1996-09-27
AU693526B2 (en) 1998-07-02
AU1868695A (en) 1995-08-15
EP0742795B1 (en) 1998-09-23
RU2155190C2 (ru) 2000-08-27

Similar Documents

Publication Publication Date Title
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
DE69319662T2 (de) Monoklonale Antikörper gegen GP130-Protein
NL300387I1 (nl) Antilichaam tegen menselijke interleukine-6-receptor
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
DK666389D0 (da) Monoklonalt antistof
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
MY107079A (en) Method of reducing immunoglobulin e responses
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
EA199900409A1 (ru) Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
DE3854999D1 (de) An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
DK69690A (da) Humane anti-rh(d) monoklonale antistoffer
DK717888A (da) Monoklonale antistoffer
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
DK49291D0 (da) Gramnegativ-bakterieendotoxinblokerende, monoklonale antistoffer
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
DK69590D0 (da) Humane anti-rh(d) monoklonale antistoffer
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
NO890116L (no) Monoklonale antistoffer.
NO872633L (no) Monoklonalt antistoff mot humant plasminogen, samt fremstilling derav.
ATE58173T1 (de) Monoklonale antikoerper und immunisierung damit.
DK220688D0 (da) Monoklonalt antistof